What: Shares of Array BioPharma, a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from ...

When it comes to buying an experienced cancer drug specialist, a bidding war is naturally expected. But in the case of Pfizer’s $11 billion deal for Array BioPharma, that didn’t happen. Still, it didn ...

What: Shares of Array BioPharma, a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ, after ...

NEW YORK (AP) — Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline ...

Array BioPharma Inc. of Boulder, Colo., and Celgene Corporation, a Summit-based biopharmaceutical company, have announced a research and development collaboration on the discovery, development and ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Array BioPharma (ARRY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (NASDAQ: ARRY) today announced a restructuring to extend its financial resources and to focus on the development of its key clinical programs.